Aethlon Medical Announces Avian Flu Treatment Application
February 08 2006 - 10:27AM
Business Wire
Aethlon Medical, Inc., (OTCBB:AEMD), a pioneer in developing
therapeutic devices for infectious disease, announced today that it
is expanding the applications of its Hemopurifier(TM) treatment
technology to include the H5N1 strain of the Avian Flu Virus. The
rapid progression of H5N1 infection allows only a brief treatment
window with antiviral drugs. The Hemopurifier will target the
direct capture of H5N1 and modulation of the immune response as a
means to treat when drugs are ineffective or unavailable. In order
to advance the H5N1 treatment application, Aethlon will manufacture
and ship the treatment devices to established influenza researchers
who will seek to establish the benefits of the Hemopurifier as a
treatment against Avian Flu. The application of the Hemopurifier to
treat Avian Flu is based on evolving research that indicates a
primary cause of death in H5N1 infection is the release of
inflammatory cells and chemicals known as a "Cytokine Storm." As a
result of cytokine storm, the immune system is hyper-activated to
the extent that the normal immune response of clearing viruses,
toxins, and infected cells becomes overshadowed by the destruction
of healthy red blood cells. Antiviral drugs are not able to shut
off a cytokine storm once it has been triggered. Thus, those
individuals with robust immune systems are actually at greater risk
than the immune compromised individuals who are most susceptible to
regular seasonal flu strains. The hyper-activation of the immune
system as a result of cytokine storm also fueled the Spanish Flu
Pandemic of 1918. That pandemic is credited with killing between
20-50 million individuals in eighteen months. The Hemopurifier
offers the potential to provide the dual benefit of clearing H5N1
and modulating the overproduction of cytokines. The Hemopurifier is
based on hemofiltration principals already indicated as a treatment
for sepsis and shock caused by cytokine overproduction. In
addition, the Hemopurifier design provides a mechanism to separate
H5N1 from circulation so that it can be captured by immobilized
affinity agents that bind to glycoproteins on the surface of the
virus. Therefore, the Hemopurifier combines the potential to tame
the immune system without destroying natural defenses, with the
ability to reduce the body burden of infectious H5N1 virus. About
Aethlon Medical Aethlon Medical is developing the first medical
device to treat infectious disease. The device, known as the
Hemopurifier(TM), is a broad-spectrum treatment countermeasure
against drug and vaccine resistant bioweapons, naturally evolving
pandemic threats, and chronic infectious disease targets such as
Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). More
information on Aethlon Medical and the Hemopurifier(TM) technology
can be found at www.aethlonmedical.com. Certain of the statements
herein may be forward-looking and involve risks and uncertainties.
Such forward-looking statements involve assumptions, known and
unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of Aethlon Medical,
Inc. to be materially different from any future results,
performance, or achievements expressed or implied by the
forward-looking statements. Such potential risks and uncertainties
include, without limitation, the Company's ability to raise capital
when needed, the Company's ability to complete the development of
its planned products, the ability of the Company to obtain FDA and
other regulatory approvals permitting the sale of its products, the
Company's ability to manufacture its products and provide its
services, the impact of government regulations, patent protection
on the Company's proprietary technology, product liability
exposure, uncertainty of market acceptance, competition,
technological change, and other risk factors. In such instances,
actual results could differ materially as a result of a variety of
factors, including the risks associated with the effect of changing
economic conditions and other risk factors detailed in the
Company's Securities and Exchange Commission filings.
Atlas Copco (PK) (USOTC:ATLRF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atlas Copco (PK) (USOTC:ATLRF)
Historical Stock Chart
From Apr 2023 to Apr 2024